Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 12/20 | 0.40 |
| ▸ | KDM6B | O15054 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1997026 | 0.89 | PDE4B (0.41) | PDE4B | |
| SCHEMBL1999152 | 0.86 | PDE4B (0.38) | PDE4BKDM4CCYP1A2SMN1; SMN2 | |
| SCHEMBL2829340 | 0.86 | KDM4C (0.41) | PDE4BKDM4CKDM6BCYP1A2SMN1; SMN2 | |
| SCHEMBL1652356 | 0.85 | PDE4B (0.63) | PDE4BSMN1; SMN2 | |
| SCHEMBL2825391 | 0.84 | KDM4C (0.40) | PDE4BKDM4CKDM6BCYP1A2SMN1; SMN2 | |
| SCHEMBL3036647 | 0.84 | PDE4B (0.54) | PDE4BKDM4CSMN1; SMN2 | |
| SCHEMBL3032862 | 0.84 | PDE4B (0.65) | PDE4BKDM4CSMN1; SMN2 | |
| SCHEMBL1995150 | 0.84 | PDE4B (0.40) | PDE4BKDM4CCYP1A2SMN1; SMN2 | |
| SCHEMBL3022923 | 0.82 | PDE4B (0.52) | PDE4BKDM4CSMN1; SMN2 | |
| SCHEMBL1997926 | 0.82 | PDE9A (0.36) | PDE4BKDM4CKDM6BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960383-B2 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL SA (ES) | 2011-06-14 | — | — | US | disclosed |
| EP-1758869-B1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ALMIRALL SA (ES) | 2010-12-22 | — | — | EP | disclosed |
| US-20080280918-A1 | Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors | ALMIRALL PRODESFARMA, SA (ES) | 2008-11-13 | — | — | US | disclosed |
| EP-1758869-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123692-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280918-A1 | Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors | PDE12, PDE4A, PDE4B | PDE4B 3/4885KDM4C 408/4885KDM6B 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.